Get started
Author

Juergen M. Schanzer

Observed names: Juergen M Schanzer, Juergen Schanzer
OpenAlex ID: A5111630699
Adenosine Kinase Inhibitors. 1. Synthesis, Enzyme Inhibition, and Antiseizure Activity of 5-Iodotubercidin Analogues
2000 · Bheemarao G. Ugarkar, Jay M. DaRe, et al. · Journal of Medicinal Chemistry · 110
A Novel Glycoengineered Bispecific Antibody Format for Targeted Inhibition of Epidermal Growth Factor Receptor (EGFR) and Insulin-like Growth Factor Receptor Type I (IGF-1R) Demonstrating Unique Molecular Properties
2014 · Juergen M. Schanzer, Katharina Wartha, et al. · Journal of Biological Chemistry · 58
Adenosine Kinase Inhibitors. 2. Synthesis, Enzyme Inhibition, and Antiseizure Activity of Diaryltubercidin Analogues
2000 · Bheemarao G. Ugarkar, Angelo J. Castellino, et al. · Journal of Medicinal Chemistry · 55
Development of tetravalent IgG1 dual targeting IGF-1R–EGFR antibodies with potent tumor inhibition
2012 · Rebecca Croasdale, Katharina Wartha, et al. · Archives of Biochemistry and Biophysics · 48
XGFR*, a novel affinity-matured bispecific antibody targeting IGF-1R and EGFR with combined signaling inhibition and enhanced immune activation for the treatment of pancreatic cancer
2016 · Juergen M. Schanzer, Katharina Wartha, et al. · mAbs · 33
Antitumor Activity of a Dual Cytokine/Single-chain Antibody Fusion Protein for Simultaneous Delivery of GM-CSF and IL-2 to Ep-CAM Expressing Tumor Cells
2006 · Juergen M. Schanzer, Iduna Fichtner, et al. · Journal of Immunotherapy · 21
Tafasitamab mediates killing of B-cell non-Hodgkin’s lymphoma in combination with γδ T cell or allogeneic NK cell therapy
2022 · Jung Hyun Her, Dominik Pretscher, et al. · Cancer Immunology Immunotherapy · 13
PDF
Targeting of CD19 By Tafasitamab Does Not Impair CD19 Directed Chimeric Antigen Receptor T Cell Activity in Vitro
2019 · Paulina Horvei, Reona Sakemura, et al. · Blood · 12
A human cytokine/single-chain antibody fusion protein for simultaneous delivery of GM-CSF and IL-2 to Ep-CAM overexpressing tumor cells.
2006 · Juergen M Schanzer, Patrick A Baeuerle, et al. · PubMed · 11
The Impact of Prior Treatment with a CD19 Targeting Monoclonal Antibody on Subsequent Treatment with CD19 Targeting CART Cell Therapy in Preclinical Models
2021 · Reona Sakemura, Paulina Horvei, et al. · Blood · 4
Correlation of baseline ENPP1 and cGAS expression in advanced solid tumors with intratumoral immune activation and clinical outcomes after treatment with the first-in-class oral ENPP1 inhibitor RBS2418, alone or in combination with pembrolizumab.
2024 · Thomas Urban Marron, Zev A. Wainberg, et al. · Journal of Clinical Oncology · 3
Functional Characterization of Gamma Delta T Cells and Allogeneic Activated NK Cells As Effector Cells for Tafasitamab (MOR208)
2019 · Jung Hyun Her, Dominik Pretscher, et al. · Blood · 2
Anti-Angiogenic Activity of a Tetravalent Bispecific Antibody (TAvi6) Targeting VEGF and Angiopoietin-2
2010 · K. Michael Weidner, Werner Scheuer, et al. · Blood · 2
Completed phase 1a dose escalation study of the first oral ENPP1 inhibitor RBS2418 immunotherapy in subjects with metastatic solid tumors.
2025 · Thomas Urban Marron, Zev A. Wainberg, et al. · Journal of Clinical Oncology · 1
PDF
Abstract LB-212: XGFR, an Fc-engineered dual signaling inhibitor targeting IGF-1R and EGFR
2011 · Katharina Wartha, Rebecca Croasdale, et al. · Cancer Research · 1
The Combination of Tafasitamab and Rituximab Increases Cytotoxicity Against Lymphoma Cells I n Vitro
2020 · Maria Patra, Christian Augsberger, et al. · Blood
Works count: 16
Citation count: 374
H-index: 9
I10-index: 9
Year
Topic
Type